Sulfonylurea K(ATP) blockade in type II diabetes and preconditioning in cardiovascular disease: Time for reconsideration

Circulation

Volumn 94, Issue 9, 1996, Pages 2297-2301

  Engler, Robert L ^a,c   Yellon, Derek M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; TOLAZAMIDE; TOLBUTAMIDE; ABC TRANSPORTER; DRUG RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GLUCOSE TRANSPORT; HUMAN; HYPOGLYCEMIA; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; DRUG ANTAGONISM; HEART INFARCTION PREVENTION; NON INSULIN DEPENDENT DIABETES MELLITUS;

ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; SULFONYLUREA COMPOUNDS;

EID: 0029662012     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2297     Document Type: Review

References (66)

1. Janbon M, Chaptal J, Vedel A, Schaap J. Montpellier Med. 1942;441:21-22.
2. Klimt CR, Knatternd GL, Meinert CL, Prout TE (UGDP). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19:747-830.
3. Schor S (UGDP). A statistician looks at the mortality results. JAMA. 1971;217:1671-1675.
4. Cornfield J (UGDP). A further statistical analysis of the mortality findings. JAMA. 1971;217:1676-1687.
5. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976-979.
6. Goetz FC. Management of adult-onset diabetes: the impact of the University Group Diabetes Program. Postgrad Med. 1972;52:63-68.
7. Harrower ADB, Clarke BF. Experience of coronary care in diabetes. Br Med J. 1976;1:126-128.
8. Soler NG, Bennett MA, Pentecost BL, Fitzgerald MG, Malins JM. Myocardial infarction in diabetics. Q J Med. 1975;173:125-132.
9. Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, Vedin A, Wilhelmsen L. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985;34:787-792.
10. Boyd AE III, Aguilar-Bryan L, Nelson DA. Molecular mechanisms of action of glyburide on the beta cell. Am J Med. 1990;89:3S-10S.
11. Caro JF. Effects of glyburide on carbohydrate metabolism and insulin action in the liver. Am J Med. 1990;89(suppl 2A):17S-25S.
12. Muller G, Dearey EA, Punter J. The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. Biochem J. 1993;289:509-521.
13. Gavin JR III. Symposium on glyburide: summary and closing remarks. Am J Med. 1990;89(suppl 2A):51S-53S.
14. Misler S, Giebisch G. ATP-sensitive potassium channels in physiology, pathophysiology, and pharmacology. Curr Opin Nephrol Hypertens. 1992;1:21-33.
15. Gram J, Jespersen J. Induction and possible role of fibrinolysis in diabetes mellitus. Semin Thromb Hemost. 1991;4:412-416.
16. Al-Awqati Q. Regulation of ion channels by ABC transporters that secrete ATP. Science. 1995;269:805-806.
17. Inagaki N, Gonoi T, Clement JP IV, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J. Reconstitution of IKATP: an inward rectifier subunit plus the suifonylurea receptor. Science. 1995;270:1166-1170.
18. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269:847-850.
19. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
20. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res. 1993;27:3-8.
21. Downey JM. Ischemic preconditioning: nature's own cardioprotective intervention. Trends Cardiovasc Med. 1992;2:170-176.
22. Shiki K, Hearse DJ, Preconditioning of ischemic myocardium: reperfusion induced arrhythmias. Am J Physiol 1987;253:H1470-H1476.
23. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;35:H1145-H1152.
24. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586-590.
25. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992;70:223-233.
26. Noma A. ATP regulated K-channels in cardiac muscle. Nature. 1983;305:147-148.
27. 1 receptors by G proteins in rat ventricular myocytes. Am J Physiol. 1990;28:H820-H826.
28. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by the ATP-sensitive potassium channels. Science. 1990;247:1341-1344.
29. Kitakaze M, Hori M, Takashimo S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation. 1993;87:208-215.
30. Meghji P, Pearson JD, Slakey LL. Regulation of extracellular adenosine production by ectonucleotidases of adult rat ventricular myocytes. Am J Physiol. 1992;32:H40-H47.
31. Headrick JP, Matherne GP, Berne RM. Myocardial adenosine formation during hypoxia: effects of ecto-5′-nucleotidase inhibition. J Mol Cell Cardiol. 1992;24:295-303.
32. Zhao ZQ, McGee S, Nakanishi K, Toombs CF, Johnston WE, Ashar MS, Vinten-Johansen J. Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit. Circulation. 1993;88:709-719.
33. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Infarct sizelimiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation. 1994;89:1237-1246.
34. Cohen M, Sneil KS, Tsuchida A, Van Wylen DGL, Downey JM. Effects of anesthesia and KATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Basic Res Cardiol. 1995;90:410-417.
35. + channel? Circ Res. 1995;77:1030-1035.
36. Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol. 1993;264:H2221-H2225.
37. 1-receptors. Circulation. 1992;86:1310-1316.
38. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res. 1993;73:1193-1201.
39. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, Engler RL. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes and injury. Circulation. 1989;80:1400-1411.
40. Ballagi-Pordany G, Koszeghy A, Koltai MZ, Aranyi Z, Pogatsa G. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res Clin Pract. 1990;8:109-114.
41. Zhang HL, Li YS, Fu SX, Yang XP. Effects of glibenclamide and tolbutamide on ischemia- and ouabain-induced arrhythmias and membrane potentials of ventricular myocardium from rat and guinea pig. Acta Pharmacol Sinica. 1991;12:398-402.
42. D' Alonzo AJ, Darbenzio RB, Hess TA, Sewter JC, Sleph PG, Grover GJ. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res. 1994;28:881-887.
43. + channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation. Eur J Pharmacol. 1994;256:115-124.
44. Tosaki A, Hellegouarch A. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. J Am Coll Cardiol. 1994;23:487-496.
45. Tosaki A, Szerdahelyi P, Engelman RM, Das DK. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther. 1993;267:1355-1362.
46. + loss and arrhythmias in rat hearts: effect of glibenclamide, a sulfonylurea. Circ Res. 1990;66:478-485.
47. + channel current in ischemic arrhythmias. Cardiovasc Drugs Ther. 1993;7(suppl 3):521-526.
48. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, D'Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1991;674:843-847.
49. Meisheri KD, Khan SA, Martin JL. Vascular pharmacology of ATP-sensitive K-channels: interactions between glyburide and K-channel openers. J Vasc Res. 1993-30:2-12.
50. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993;72:1293-1299.
51. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation. 1994;90:2993-3000.
52. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88:1264-1272.
53. Yellon DM, Baxter GS. Window of protection or delayed preconditioning phenomenon: future horizons for myocardial protection. J Mol Cell Cardiol. 1995;27 (in press).
54. Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DAG, Li R-K. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia. Cardiovasc Res. 1994;28:1285-1291.
55. Muller DWM, Topol EJ, Califf RM, Sigmon KM, Gorman L, George BS, Kereiakes DJ, Lee KL, Ellis SG. Relationship between antecedent angina pectoris and short term prognosis after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990;119:224-231.
56. Kloner R, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Barstem S, Gibson M, Poole WK, Cannon CP, McCabe CH, Braunwald E. Previous angina alters in-hospital outcome in T1MI 4: a clinical correlate to preconditioning? Circulation. 1995;91:37-45.
57. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation. 1995;91:291-297.
58. Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, Higashino Y, Fuji K, Minamino T. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of 'preconditioning.' J Am Coll Cardial. 1995;25:1076-1083.
59. Deutsch E, Berger M, Kussmaul W, Hirshfeld J, Herrman H, Laskey W. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Circulation. 1990;82:2044-2051.
60. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C. Improved myocardial ischemic response and enhanced collateral circulation with repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578-586.
61. + channel blocker. Circulation. 1994;90:700-705.
62. MacAlpin RN, Kattus AA. Adaptation to exercise in angina pectoris. Circulation. 1966;33:183-201.
63. Marber MS, Joy MD, Yellon DM. Is warm up in angina ischemic preconditioning? Br Heart J. 1994;72:213-215.
64. Yellon D, Alkhulaifi A, Pugsley W. Preconditioning the human myocardium. Lancet. 1993;342:276-277.
65. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res. 1993;27:43-47.
66. Haeusler G, Lues I. Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994;15(suppl C): 82-38.